A detailed history of Pallas Capital Advisors LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 30,206 shares of ABBV stock, worth $4.95 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
30,206
Previous 26,832 12.57%
Holding current value
$4.95 Million
Previous $4.16 Million 32.28%
% of portfolio
0.24%
Previous 0.23%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

BUY
$159.82 - $182.1 $539,232 - $614,405
3,374 Added 12.57%
30,206 $5.5 Million
Q4 2023

Jan 22, 2024

SELL
$137.6 - $154.97 $425,596 - $479,322
-3,093 Reduced 10.34%
26,832 $4.16 Million
Q3 2023

Nov 01, 2023

BUY
$133.59 - $154.65 $898,927 - $1.04 Million
6,729 Added 29.01%
29,925 $4.46 Million
Q2 2023

Jul 26, 2023

BUY
$132.51 - $164.9 $2.3 Million - $2.86 Million
17,337 Added 295.9%
23,196 $3.13 Million
Q1 2023

May 02, 2023

BUY
$144.61 - $166.54 $333,326 - $383,874
2,305 Added 64.86%
5,859 $933,000
Q4 2022

Jan 24, 2023

BUY
$138.31 - $165.87 $3,872 - $4,644
28 Added 0.79%
3,554 $0
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $4,160 - $4,771
31 Added 0.89%
3,526 $509,000
Q2 2022

Aug 11, 2022

SELL
$137.62 - $174.96 $24,496 - $31,142
-178 Reduced 4.85%
3,495 $519,000
Q1 2022

Apr 20, 2022

BUY
$131.98 - $163.75 $158,639 - $196,827
1,202 Added 48.64%
3,673 $596,000
Q4 2021

Feb 01, 2022

SELL
$107.43 - $135.93 $44,690 - $56,546
-416 Reduced 14.41%
2,471 $326,000
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $30,643 - $34,784
-288 Reduced 9.07%
2,887 $339,000
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $137,509 - $153,193
1,307 Added 69.97%
3,175 $365,000
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $191,096 - $210,374
1,868 New
1,868 $217,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $290B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Pallas Capital Advisors LLC Portfolio

Follow Pallas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pallas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pallas Capital Advisors LLC with notifications on news.